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Endolysins are lytic enzymes produced by bacteriophages with their ability to
degrade the cell wall of bacterial hosts. Endolysin (LysABP-01) from Acinetobacter
baumannii bacteriophage ØABP-01 was cloned, overexpressed and characterized.
Endolysin LysABP-01 has a globular structure consisting of lysozyme-like (N-acetyl-
β-D-muramidase) catalytic domain. It contains 185 amino acids which correspond to a
21.1 kDa protein. The lytic activity of the recombinant endolysin protein was determined
by a plate lysis assay for its ability to lyse the autoclaved cell (crude cell wall) of the
different bacterial species. LysABP-01 can degrade the crude cell wall of A. baumannii
strains, Escherichia coli and Pseudomonas aeruginosa but not of Staphylococcus
aureus. The antibacterial activity of LysABP-01 and its synergism with various antibiotics
were tested. The results exhibited elevated antibacterial activity in a combination of
the sub-MIC LysABP-01 and colistin. The checkerboard assay for measuring antibiotic
synergy of LysABP-01 and colistin was performed. This combination was synergistic
against various drug-resistant strains of A. baumannii (FIC index < 0.5). In summary,
our study highlights the ability of LysABP-01 endolysin to hydrolyze the A. baumannii
cell wall and its synergistic interaction with colistin.
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INTRODUCTION
Acinetobacter baumannii has emerged as a clinically significant pathogen that resistance to most
available antibiotics. The increasing prevalence of multidrug-resistant A. baumannii (MDRAB)
and extensively drug-resistant A. baumannii (XDRAB) infections has been reported worldwide
(Perez et al., 2007). To date, colistin and tigecycline remain the most active antibiotics against
drug-resistant A. baumannii (Henwood et al., 2002; Falagas and Kasiakou, 2005). However, the
utilization of these drugs is limited due to high rates of toxicity and development of resistance
(Falagas and Kasiakou, 2005; Navon-Venezia et al., 2007; Cai et al., 2012). Therefore, alternative
antibacterial agents for treatments of MDRAB and XDRAB are urgently required.
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Endolysins are lytic enzymes produced by bacteriophages
during the last step of their replicative cycle. The enzymes
degrade the cell wall of bacterial hosts and lead to cell lysis and
phage progeny release (Young, 1992). Endolysins are classified as
a new class of antimicrobials for the treatment of drug-resistant
bacterial infection because of their rapid action, low evidence of
resistance development and low cytotoxicity against mammalian
cells (Schmelcher et al., 2012). A number of studies have
demonstrated the efficiency of recombinant phage endolysins
against gram-positive pathogens in vitro and in animal models.
In contrast, applications of endolysins specific to gram-negative
bacteria are limited because the outer cell membrane (OM)
prevents exogenously applied endolysins from attracting the
peptidoglycan layer (Fischetti, 2010; Schmelcher et al., 2012).
Thus, many studies have focused on the enhancement of
OM permeability using chelators, weak organic acids or high
hydrostatic pressure (Briers et al., 2008, 2011; Oliveira et al., 2014,
2016). The chelator EDTA is very useful as an OM permeabilizer
because of its ability to destabilize the lipopolysaccharide
structure (Briers et al., 2011). However, the potential for future
applications of an endolysin-EDTA combination is limited only
for the topical treatment of localized bacterial infections, such as
burn wound, eye and ear infections. The use of this combination
is not suitable for the treatment of systemic infections as
EDTA inhibits the blood clotting at the low concentration
(Triantaphpyllopoulos et al., 1955). Combinations of the lytic
enzyme with other antibacterials may produce synergistic effects
or reduce the dose of a single agent (Djurkovic et al., 2005).
We previously characterized ØABP-01, a lytic phage which
infects MDRAB strains (Kitti et al., 2014). We found that the
ØABP-01 genome contains the endolysin encoding gene. In this
study, we examined the antibacterial activity of LysABP-01 alone
and in combination with conventional antibiotics against both
MDRAB and XDRAB strains.
MATERIALS AND METHODS
Bacteriophage, Bacterial Strains,
Plasmids and Growth Conditions
Bacteriophage, bacterial strains and plasmids used in this study
are listed in Table 1. A. baumannii strain AB 1589 was used as the
host for the ØABP-01 phage propagation. Four additional isolates
were collected from difference hospitals in Thailand (Table 2). All
isolates were identified on the species level by using biochemical
tests and the PCR detection of the blaOXA−51 gene (Brown et al.,
2005). All bacterial strains were grown in Luria-Bertani (LB)
broth or agar (Hardy Diagnostics, Santa Maria, CA, USA) at
37◦C.
Cloning of lysABP-01
Bacteriophage ØABP-01 genomic DNA was prepared according
to the method reported in our previous study (Kitti et al., 2014).
The endolysin gene lysABP-01 (accession no. KF548002) was
PCR amplified by using the phage DNA as a template with
primers EndolysinABP-F and EndolysinABP-R (Table 1) which
generated a 558 bp PCR product flanked by the restriction sites
BamHI and EcoRI. The resulting PCR product was cut with
BamHI/EcoRI restriction enzymes and cloned into the plasmid
pBluescript II (pBluescript-lysABP-01). The lysABP-01 in the
pBluescript II was then subcloned into pRSETa expression vector
(pRSET-lysABP-01). All initial DNA cloning procedures were
carried out in Escherichia coli DH5α and then transformed into
E. coli BL21 (DE3) pLysS. Restriction digestions and sequencing
were used to verify the integrity of the cloned fragment.
Overexpression and Purification of
LysABP-01
Log phase culture of E. coli BL21 (DE3) pLysS containing pRSET-
lysABP-01 (A600 ∼ 0.5) was induced by the addition of IPTG
to the final concentration of 1 mM. After incubation for 4 h
at 37◦C, cells were pelleted, washed and frozen at −80◦C. The
expressed protein was found in the insoluble cellular fraction,
and was thus purified from the inclusion bodies. Thawed cells
were resuspended in lysis buffer (145 mM NaCl, 20 mM Tris-
Cl, pH 7.4) and disrupted by sonication with a ultrasonic cell
disrupter (Sonic & Material Inc, Newtown, CT, USA). The soluble
fraction was removed by centrifugation (5,000 × g). The pellets
containing the inclusion bodies were solubilized in binding buffer
containing urea (6 M urea, 500 mM NaCl, 20 mM Tris-Cl, 5 mM
imidazole, pH 7.9). The solubilized recombinant protein was
purified on the affinity chromatography column (His·Bind Kits,
Novagen, Germany) under denaturing condition according to the
manufacturer’s instructions. The purified protein fractions were
pooled and then diluted with four times volume of renaturation
buffer (PBS containing 0.5 mM PMSF, 0.3 M arginine, 1%
glycerol). The diluted protein was dialyzed against dialysis buffer
(PBS containing 1 M urea, 1% glycerol) for overnight and then
dialyzed against storage buffer (PBS containing 1% glycerol).
The protein obtained after dialysis was concentrated using the
vivaspin500 concentrator (GE Healthcare, UK). The purity of
protein was checked by 12% SDS-PAGE, followed by staining of
the SDS-PAGE gels with coomassie brilliant blue G-250 and the
Pierce 6xHis Protein Tag Stain Reagent Set (Thermo sciencetific,
USA). Protein concentrations were determined by the Bio-Rad
protein assay (BioRad, Hercules, CA, USA).
Antibiotic Susceptibility Testing
The disk diffusion method was performed for all A. baumannii
isolates to determine the susceptibility of amikacin (30 µg),
cefotaxime (30 µg ), ceftazidime (30 µg), ceftriaxone (30 µg),
cefepime (30 µg), ciprofloxacin (5 µg), gentamicin (10 µg),
imipenem (10 µg), meropenem (10 µg), trimethoprim/
sulfamethoxazole (1.25/23.75 µg), tetracycline (30 µg),
cefoperazone/sulbactam (105 µg), piperacillin/tazobactam
(100/10 µg), colistin (10 µg) and tigecycline (15 µg) (Oxoid
discs, UK). The results were interpreted according to the
Clinical and Laboratory Standards Institute (CLSI) guidelines
(Clinical and Laboratory Standards Institute [CLSI], 2014).
The antibiotic resistance profile was classified as multidrug-
resistant A. baumannii (MDRAB) or extensively drug-resistant
A. baumannii (XDRAB) based on a previously published
description (Magiorakos et al., 2012).
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TABLE 1 | Bacteriophage, bacterial strains, plasmids and primers used in this study.
Strains, phage, plasmids, or primers Relevant characteristic(s), function, or sequence Source or reference
Bacteriophage
ØABP-01 A. baumannii phage from the waste water treatment plant Kitti et al., 2014
Bacterial strains
ATCC 19606 A. baumannii reference strain ATCC
AB 1589 MDRAB strain, host for ØABP-01 Kitti et al., 2015
DH5∝ E. coli strain used for cloning Novagen, Germany
BL21 (DE3) pLysS E. coli strain used for protein overexpression, Camr Novagen, Germany
ATCC 25922 E. coli reference strain ATCC
ATCC 27853 Ps. aeruginosa reference strain ATCC
ATCC 6538 S. aureus reference strain ATCC
Plasmids
pBluescript II DNA cloning and sequencing vector, Ampr Fermentas, USA
pRSETa Overexpression vector, Ampr Invitrogen, USA
pBluescript-lysABP-01 pBluescript II containing the lysABP-01 This study
pRSET-lysABP-01 pRSETa containing the lysABP-01 This study
Primers
EndolysinABP-F 5′-GCGGATCCATGATTCTGACTAAAGACGGATTTAGTATT-3′ This study
EndolysinABP-R 5′-GCGAATTCCTATAAGCTCCGTAGAGCACGTTC-3′
blaOXA−51-F 5′-TAATGCTTTGATCGGCCTTG-3′ Brown et al., 2005
blaOXA−51-R 5′-TGGATTGCACTTCATCTTGG-3’
TABLE 2 | Characteristics of clinical A. baumannii strains and their susceptibility to the LysABP-01 alone and in combination with colistin.
Strains ID Year of isolation/Hospital Drug resistance type MICcolistin (µg/ml) MICLysABP−01 (µM) FICI
Alone Combined Alone Combined
AB 1589 2007/H1 MDRAB 1 0.125 20 1.250 0.188
AB 0022 2013/H2 XDRAB 2 0.250 20 1.250 0.188
AB 0140 2014/H3 XDRAB 1 0.125 10 0.3125 0.156
AB 0269 2014/H4 XDRAB 1 0.125 10 0.625 0.188
AB 0405 2015/H5 XDRAB 0.5 0.0625 10 0.3125 0.156
Minimum Inhibitory Concentration (MIC)
Minimum inhibitory concentrations was determined by the
CLSI recommended broth microdilution techniques in Mueller-
Hinton broth (HiMedia) (Clinical and Laboratory Standards
Institute [CLSI], 2014). The antibiotics; ciprofloxacin, imipenem,
colistin, chloramphenicol, gentamycin, erythromycin and
tetracycline obtained from Sigma–Aldrich (St. Louis, MO, USA)
were used. The MIC was defined as the lowest concentration of
antibiotic that inhibit the bacterial growth. All MIC experiments
were performed in duplicate and used E. coli ATCC 25922 as
a quality control strain. The MIC value was used to calculate
sub-MIC values (0.25× the MIC) for the next experiment.
Plate Lysis Assay
Plate lysis assay was performed as described previously (Donovan
et al., 2006) with some modifications. Bacterial cells of
A. baumannii ATCC 19606, A. baumannii AB 1589, Escherichia
coli ATCC 25922, Pseudomonas aeruginosa ATCC 27853 or
Staphylococcus aureus ATCC 6538 in mid log phase were
collected, washed once and suspended in PBS. The suspension
was then autoclaved and centrifuged. The resulting pellet was
resuspended in PBS (2% [vol/vol] of initial culture volume) and
used as the substrate. Ten microliters of purified LysABP-01
(10 µM) was spotted onto the agar plate (1.5%) containing the
substrate (5%). An equal volume of 10 µM egg white lysozyme
was used as a positive control whereas PBS and storage buffer
were used as negative controls. The spotted plates were incubated
at room temperature.
Antibacterial Activity
Bacterial growth inhibition assay was performed as described
previously (Knezevic and Petrovic, 2008) with little
modifications. Bacterial colonies were transferred to Mueller
Hilton broth (HiMedia) and cultured at 37◦C for 4 h to
reach mid-log phase. From these cultures, the turbidity of cell
suspensions were adjusted to an equivalent 0.5 McFarland
standard as measured by absorbance (0.08–0.1 at 625 nm),
corresponding to approximately 108 CFU/ml. The adjusted cell
suspensions were diluted 1:100 in double strengthen Mueller
Hilton broth, and 50 µl was inoculated into each well (a final
cell density ∼ 5 × 105 CFU/ml) in a microplate. The inoculum
density was confirmed by plate count. Appropriate dilutions
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of the LysABP-01 in PBS (25 µl) were added into wells, and
the same volume of PBS or antibiotic (0.25 × the MIC) was
added. Sample-inoculated microplates were incubated at 37◦C
overnight. After incubation, 25 µl of 0.1% sterilized TTC (Sigma
Chemical Co, Saint Louis, MO, USA) was added into each well
and incubated for additional 3 h. The absorbance was read at
540 nm using a Synergy 2 multi-mode microplate reader (BioTek
Instruments, Winooski, VT, USA). Each test was performed in
triplicate.
Checkerboard Synergy Testing
Interactions between LysABP-01 and the selected antibiotic were
assessed by the checkerboard broth microdilution method as
previously described (Pillai et al., 2005). Testing was performed
in Mueller-Hinton broth, with a final inoculum of 5 × 104 CFU
per well in microplates. LysABP-01 and the selected antibiotic
were diluted twofold horizontally and vertically, respectively. The
concentrations of the selected antibiotic and LysABP-01 ranged
from 0.0625 – 2 × MIC and 0.0156 – 2 × MIC, respectively.
Microplates were incubated overnight at 37◦C. After incubation,
25 µl of 0.1% sterilized TTC (Sigma Chemical Co, Saint Louis,
MO, USA) was added into each well and incubated for 3 h.
Test results were used to calculate the fractional inhibitory
concentrations (FICs) and FIC index (FICI). FICs of LysABP-
01 and the selected antibiotic were plotted on the x/y plot to
generate an isobologram. A FICI was interpreted as follows:≤0.5,
synergy; >0.5 – ≤1.0, additive; >1.0 – ≤ 2.0, indifference; and
>2.0, antagonism (Pillai et al., 2005).
FIGURE 1 | Amino acid sequence alignment of LysABP-01. The sequences used for alignment analysis were LysAB2 (from phage φAB2, accession no.
ADX62345), PlyAB1 (from phage Abp1, accession no.YP_008058242) and LysABP-01 (from phage ØABP-01, accession no. AHG30899). Eleven mutation residues
are indicated by asterisks (∗), five of which are found in conserved domain at positions 96, 100, 103, 108, and 111.
FIGURE 2 | Analysis of histidine-tagged LysABP-01. (A) SDS-PAGE analysis for expression and purification of LysABP-01. (B) Fluorescent stain for detection of
His6-tagged LysABP-01 on a SDS-PAGE gel. Lane M, BLUeye prestained protein ladder; Lanes 1, un-induced bacterial lysate; Lane 2, IPTG-induced bacterial
lysate; Lane 3, the purified Lys-ABP-01 after dialysis. (C) Plate lysis assay of the purified LysABP-01. Egg white lysozyme (EWL), A. baumannii ATCC19606 (ATCC
19606), A. baumannii AB 1589 (AB 1589), E. coli (ATCC 25922), Ps. aeruginosa (ATCC 27853) and S. aureus (ATCC 6538).
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RESULTS
Characterization of the LysABP-01
The endolysin gene of the phage ØABP-01, named lysABP-
01, has been previously detected and sequenced (accession no.
KF548002). The LysABP-01 contains 185 amino acid residues,
which corresponds to a 21.1 kDa protein. Conserved domain
analysis using the Pfam database has revealed the presence
of a lysozyme-like (N-acetyl-β-D-muramidase) catalytic domain
between residues 75 and 128 of LysABP-01. A ClustalW2
alignment of LysABP-01 with two phage endolysins showed high
similarity in the conserved domain region (Figure 1). Although
these three endolysins share high sequence similarity, 5 out of 11
amino acid mutations were found in the conserved region among
them (Figure 1).
Over-Expression, Purification, and Lytic
Activity of LysABP-01
After induction with IPTG, the expressed LysABP-01 was
detected by SDS-PAGE analysis (Figure 2A). The presence
of a histidine-tag in the expressed recombinant proteins was
confirmed by staining with the Pierce 6xHis Protein Tag Stain
Reagent Set (Figure 2B). We found that most of the expressed
LysABP-01 was insoluble protein. The insoluble protein fraction
was solubilized and purified using affinity chromatography. The
purified LysABP-01 was refolded and concentrated. The lytic
activity and spectrum of LysABP-01 were tested using the plate
lysis assay and autoclaved cells (crude cell wall) from the log
phase cells of gram-positive and gram-negative bacteria, which
were used as substrates. The results showed that LysABP-01 had
strong lytic activity toward two A. baumannii strains (ATCC
19606 and AB 1589) and weaker activity against reference
strains of E. coli and Ps. aeruginosa (Figure 2C). In addition,
no lysis was detected in a gram-positive strain, S. aureus
(Figure 2C).
Antibacterial Activity of LysABP-01 and
Its Synergism with Antibiotics
The MIC of purified LysABP-01 was tested using bacterial
growth inhibition assays for its ability to inhibit the growth
of viable cells of the MDRAB strain. The results indicated
that the LysABP-01 can prevent the growth of AB1589 with
a MIC of 20 µM (Figure 3; Table 2). The interactions
between LysABP-01 and seven antibiotics were screened
by growth inhibition assay at 0.25 × the MIC of two
agents (Supplementary Table S1). As shown in Figure 4A,
only the combination of LysABP-01 plus colistin exhibited
elevated antibacterial activity (nearly 100% of growth inhibition
rate). In order to verify these results, we performed a
checkerboard assay for measuring antibiotic synergy. The
FICI value for the combination of LysABP-01 and colistin
(0.0625/0.125 × the MIC) was determined as 0.188, which
indicates synergism (Table 2). Test results were also represented
by the isobologram generated by plotting the FICs of LysABP-01
and colistin. The isobologram is presented in Figure 4B and
it shape being concave, suggests that the two antimicrobials
FIGURE 3 | Antibacterial activity of LysABP-01. (A) Bacterial growth
inhibition activity of varying concentrations of LysABP-01. The bar graph
depicts the percent growth inhibition and represents the mean
percentage ± SD of triplicate experiments. (B) The representative microplate
image of TTC staining.
had a synergistic effect against the representative MDRAB
strain.
The Susceptibility of XDRAB Strains to
LysABP-01 Combined with Colistin
The selected strains of A. baumannii were obtained from
various hospitals located in different areas of Thailand. All
four isolates were positive for the species-specific blaOXA−51
gene (data not shown). The results from the disk diffusion
method revealed that four A. baumannii isolates were resistant
to all tested antibiotics except colistin and tigecycline. Thus,
these strains were classified as XDRAB (Table 2). The in vitro
activity of LysABP-01 against a broad range of A. baumannii
strains was studied. The results of the antimicrobial susceptibility
testing of different A. baumannii strains to LysABP-01 alone
and in combination with colistin are shown in Table 2
and Supplementary Figure S1. By a checkerboard test, the
FICI and isobologram of the colistin-LysABP-01 combination
showed synergistic against all tested XDRAB strains (Table 2;
Supplementary Figure S1).
DISCUSSION
The emergence of drug-resistant bacteria is a therapeutic
problem. Bacteriophages and their endolysins have been
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FIGURE 4 | The results of screening and confirmatory testing for synergistic interaction. (A) The growth inhibition rate (the bar graph) of LysABP-01
combined with seven antibiotics. Data are expressed as the mean percentage ± SD of triplicate experiments. Phosphate buffer saline (PBS), ciprofloxacin (CIP),
imipenem (IMP), colistin (COL), chloramphenicol (CHLO), gentamycin (GEN), erythromycin (ERY) and tetracycline (TET). (B) The isobologram of the checkerboard
assay. FIC values derived from combinations of LysABP-01 and colistin were used to plot the isobologram. The dashed line illustrates the theoretical additive
interaction between two agents.
recognized as alternative therapeutic compounds for combating
drug-resistant bacterial infections. In our previous work, three
phages infecting MDRAB were isolated and characterized (Kitti
et al., 2014). We found the ØABP-01 phage belonged to
Podoviridae family. This phage had shown a good lytic activity
on MDRAB and its genome contains the endolysin gene,
named lysABP-01, which was further studied. In silico sequence
analysis revealed that the LysABP-01 was conserved in other
endolysins from Acinetobacter phage such as LysAB2, PlyAB1
and ABgp46 (Lai et al., 2011; Huang et al., 2014; Oliveira
et al., 2016). The lysozyme-like catalytic domain of LysABP-
01 is a N-acetyl-β-D-muramidase that cleaves β-1, 4-glycosidic
bonds between N-acetylmuramic acid and N-acetylglucosamine
of the peptidoglycan (Schmelcher et al., 2012). As illustrated
in Figure 1, 11 mutation residues among three endolysins,
especially five points in the conserved domain, may contribute
to the enzyme’s catalytic function.
The recombinant LysABP-01 was located in the insoluble
fraction as inclusion bodies due to its toxicity to host cells
(García et al., 2010). We have successfully purified and refolded
LysABP-01 from inclusion bodies. The result from plate lysis
assay revealed that the recombinant LysABP-01 was able
to digest crude cell wall from A. baumannii reference and
MDRAB strains. This result was consistent with the findings
from conserved domain analysis. However, LysABP-01 was
active against other gram-negative bacteria but not able to
hydrolyze crude cell walls of gram-positive bacteria, which
corresponded with previous reports (Lim et al., 2014; Oliveira
et al., 2014).
Enzyme activity of LysABP-01 was not only active against
crude cell wall but also able to inhibit the growth of viable
cells. The antibacterial activity of LysABP-01 was in agreement
with the report of Lai and co-workers (Lai et al., 2011). In
their study, they found that the presence of 500 µg/ml of the
LysAB2 could reduce the cell viability of A. baumannii to less
than 1% (Lai et al., 2011), while in our study we found that the
presence of 20 µM (∼500 µg/ml) of LysABP-01 inhibited the
growth of A. baumannii. Gram negative bacteria have an OM
that can protect peptidoglycan from the direct contact of lytic
enzymes. Thus, the combination approach can be used to increase
the efficacy of lytic enzymes. Previous studies have reported
that the combination of colistin with other antimicrobials, such
as vancomycin (Gordon et al., 2010), teicoplanin (Wareham
et al., 2011), and daptomycin (Galani et al., 2014) produced
synergistic effects against MDRAB strains. Because only the
combination of LysABP-01 and colistin was found to increase
antibacterial activity (Figure 4B), the checkerboard assay was
not carried out in all combinations. The in vitro combination
of colistin with LysABP-01 in this study revealed a synergistic
interaction against MDRAB, AB 1589. We also found that
this protein is effective against a broad range of XDRAB
for both exclusive and in combination treatments. Moreover,
the MICs of LysABP-01 were reduced up to 32-fold, while
the MICs of colistin were reduced up to eightfold in the
combination (Table 2). Colistin, also called polymyxin E, is
a cyclic lipopeptide antibiotic consisting of a cationic peptide
ring and a lipophilic fatty acid tail. The positively charged
molecules of this drug interact with the negatively charged
lipid A phosphates and displace the divalent cations (Mg2+
and Ca2+) in the lipopolysaccharide, which is essential for
the OM stability. This interaction causes OM damage and
leakage of cellular components leading to cell death (Falagas
and Kasiakou, 2005). The cell membrane destabilizing activity
of colistin could be exploited to promote the penetration of
the endolysin through the OM toward its target in the cell
wall. Although polymyxins are often the most effective drugs
for MDRAB and XDRAB treatment, the use of these drugs
in clinical practice is very restricted because of their effects
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on resistance development and nephrotoxicity or neurotoxicity
(Falagas and Kasiakou, 2005; Cai et al., 2012). In this work, we
have demonstrated that the colistin-LysABP-01 combination can
produce synergy with a wide range of strains, reduce the dose of
two agents, and may decrease the toxicity of colistin. Thus, the
synergistic results illustrate the potential for future therapeutic
use of this combination.
CONCLUSION
This study shows that LysABP-01 contains antibacterial
activity against A. baumannii. This enzyme has a
synergistic interaction with colistin, an antibiotic with a
directed action against the bacterial cell membrane. The
implication of this study is that LysABP-01 will work as
an alternative agent in combination with colistin against
A. baumannii.
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FIGURE S1 | In vitro synergistic activity of LysABP-01 combined with
colistin against XDRAB strains. (A) The representative checkerboard plates.
(B) The isobolograms representing the drug interaction of LysABP-01 plus colistin.
FIC values derived from combinations of LysABP-01 and colistin were used to plot
the isobologram. The dashed line illustrates the theoretical additive interaction
between two agents.
TABLE S1 | MICs of conventional antibiotics against A. baumannii AB
1589.
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